Laboratory of Cardiovascular Regeneration, Division of Cardiovascular Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea School of Medicine, Seoul, South Korea.
Circ J. 2012;76(6):1307-12. doi: 10.1253/circj.cj-11-1479. Epub 2012 May 19.
Ischemic heart disease (IHD) accelerates cardiomyocyte loss, but the developing stem cell research could be useful for regenerating a variety of tissue cells, including cardiomyocytes. Diverse sources of stem cells for IHD have been reported, including embryonic stem cells, induced pluripotent stem cells, skeletal myoblasts, bone marrow-derived stem cells, mesenchymal stem cells, and cardiac stem cells. However, stem cells have unique advantages and disadvantages for cardiac tissue regeneration, which are important considerations in determining the specific cells for improving cell survival and long-term engraftment after transplantation. Additionally, the dosage and administration method of stem cells need to be standardized to increase stability and efficacy for clinical applications. Accordingly, this review presents a summary of the stem cell therapies that have been studied for cardiac regeneration thus far, and discusses the direction of future cardiac regeneration research for stem cells.
缺血性心脏病（IHD）会加速心肌细胞的损失，但不断发展的干细胞研究可能对多种组织细胞（包括心肌细胞）的再生有用。已经报道了用于 IHD 的多种来源的干细胞，包括胚胎干细胞、诱导多能干细胞、骨骼肌成肌细胞、骨髓来源的干细胞、间充质干细胞和心脏干细胞。然而，干细胞在心脏组织再生方面具有独特的优势和劣势，这是确定特定细胞以提高细胞存活率和移植后长期植入的重要考虑因素。此外，还需要标准化干细胞的剂量和给药方法，以提高其在临床应用中的稳定性和疗效。因此，本综述总结了迄今为止用于心脏再生的干细胞治疗方法，并讨论了未来干细胞心脏再生研究的方向。
